ESR1 and cancer: De novo anti‐oestrogen resistance is observed mainly in ER‐/PR‐ tumours, but cancer cells can sometimes switch the phenotype from ER+ to ER−.37, 38 Based on failure to endocrine therapy, the patients can be treated with chemical therapeutic agents.